Fig. 2: Change in target lesion size after treatment.

Waterfall plot of best percentage change in tumor size in a all evaluable patients (n = 26) and b patients with ESR1 mutations (n = 10), and spider plot of change in tumor size during treatment overtime in c all evaluable patients (n = 26) and d patients with ESR1 mutations; e baseline contrast-enhanced axial CT image of liver lesions at baseline and 6 months after treatment with AC699 200 mg QD in a patient harboring an ESR1 mutation. Red arrows indicate the location of the tumor. Mut mutated, PD progressive disease, PR partial response, pt patient, SD stable disease; *, The patient had a 23% increase in the size of a target node which was an increase of <5 mm, thus SD); #, patients had no decrease in the size target lesions and a response of SD; °, patients <20% who had PD, due to developed new lesions. Waterfall plots (a, b) represent patients with target lesions at baseline and at least one adequate post-baseline assessment. The largest decrease or smallest increase represents the best response to treatment. Spider plots (c, d) represent patients with target lesions at baseline and at least one adequate post-baseline assessment. Source data are provided as a Source data file.